- Home
- NERV vs TLPH Comparison
NERV vs TLPH Comparison
Compare NERV & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- TLPH
- Stock Information
- Founded
- NERV 2007
- TLPH 2005
- Country
- NERV United States
- TLPH United States
- Employees
- NERV N/A
- TLPH N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- TLPH Health Care
- Exchange
- NERV Nasdaq
- TLPH Nasdaq
- Market Cap
- NERV 12.6M
- TLPH 10.6M
- IPO Year
- NERV 2014
- TLPH 2011
- Fundamental
- Price
- NERV $1.73
- TLPH $0.45
- Analyst Decision
- NERV Hold
- TLPH Strong Buy
- Analyst Count
- NERV 1
- TLPH 1
- Target Price
- NERV $5.00
- TLPH $6.00
- AVG Volume (30 Days)
- NERV 12.1K
- TLPH 44.3K
- Earning Date
- NERV 08-05-2025
- TLPH 08-13-2025
- Dividend Yield
- NERV N/A
- TLPH N/A
- EPS Growth
- NERV N/A
- TLPH N/A
- EPS
- NERV 0.83
- TLPH N/A
- Revenue
- NERV N/A
- TLPH $27,000.00
- Revenue This Year
- NERV N/A
- TLPH N/A
- Revenue Next Year
- NERV N/A
- TLPH $14,533.26
- P/E Ratio
- NERV $2.06
- TLPH N/A
- Revenue Growth
- NERV N/A
- TLPH N/A
- 52 Week Low
- NERV $1.15
- TLPH $0.43
- 52 Week High
- NERV $3.50
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- NERV 50.22
- TLPH 41.77
- Support Level
- NERV $1.57
- TLPH $0.45
- Resistance Level
- NERV $1.88
- TLPH $0.52
- Average True Range (ATR)
- NERV 0.09
- TLPH 0.03
- MACD
- NERV -0.02
- TLPH -0.00
- Stochastic Oscillator
- NERV 52.03
- TLPH 23.33
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.